Lowering the hurdle to success against solid tumors
PIPELINE
Capturing the untapped therapeutic potential of ADCs and other systemic treatments
Tagworks’ lead program, TGW101, targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors, which cannot be effectively addressed with current ADC technologies. In addition, our pipeline includes discovery phase programs on other solid-tumor-targeted ADCs as well as radiopharmaceuticals, including a HER2-targeted radioimmunotherapeutic.
Our pipeline
Lead ADC Program: TGW101
Our lead program, TGW101, targets TAG72, a clinically validated, non-internalizing, pan-carcinoma target that is widely expressed in a range of epithelial-derived human cancers such as breast, colorectal, stomach, lung, pancreatic, prostate, and ovarian cancers. As it is relatively stable on the extracellular cell membrane, it has so far not been effectively addressed with current ADC technologies.
TGW101-ADC consists of a TAG72-binding diabody conjugated with TCO-linked monomethyl auristatin E (MMAE) toxin. MMAE has a well understood and manageable safety profile, and a well-documented bystander effect.
In TGW101 therapy, the ADC is administered first and allowed to bind the tumor and clear from circulation, after which the trigger molecule is injected systemically, resulting in cleavage of the tumor-bound ADC and passive distribution of MMAE into the surrounding tumor cells.
Our preclinical research indicates that on-tumor activation of TGW101-ADC leads to high and sustained concentrations of auristatin within the tumor microenvironment, affording a strong therapeutic effect, while mice that received an analogous protease-cleavable ADC progressed nearly as fast as the control group.
We are currently evaluating this program in IND-enabling studies.
EXPANDED ACCESS POLICY
Tagworks products are investigational and have not been approved as safe and effective by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or any other regulatory agency. The effectiveness of investigational products in treating the intended condition is uncertain. At this time, Tagworks is focused on conducting clinical trials with the goal of making these therapies broadly available to patients with unmet medical needs.
Expanded Access (also known as compassionate use) provides investigational medicines to patients with serious or life-threatening conditions who are not eligible for clinical trials and lack alternative treatment options. Currently, Tagworks does not accept applications for expanded access. Our investigational products can only be accessed through participation in the ongoing clinical trials. We encourage patients to consult with their healthcare providers and consider participation in Tagworks’ clinical trials, which remains the most appropriate way to access our investigational therapies.
Additional details regarding Tagworks’ active clinical trials can be found at www.clinicaltrials.gov.
Curious about what we do? Get in touch!
Contact
T +31 85 800 8550
info@tagworkspharma.com
Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED Nijmegen
The Netherlands
Stay updated
© Tagworks Pharmaceuticals, 2025 | Terms of use | Privacy Statement | Design by Ape to Zebra